Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9931209 | 1.00 | HRH3 (0.34) | HRH3CXCR4 | |
| SCHEMBL2636046 | 1.00 | HRH3 (0.34) | HRH3CXCR4 | |
| SCHEMBL9931712 | 1.00 | HRH3 (0.34) | HRH3CXCR4 | |
| SCHEMBL16538809 | 0.84 | KMT2A (0.35) | — | |
| SCHEMBL16538617 | 0.82 | KMT2A (0.35) | HRH3 | |
| SCHEMBL16538419 | 0.82 | KMT2A (0.35) | HRH3 | |
| SCHEMBL16538738 | 0.79 | KMT2A (0.38) | — | |
| SCHEMBL16538541 | 0.79 | KMT2A (0.35) | HRH3 | |
| SCHEMBL16538558 | 0.79 | KMT2A (0.35) | HRH3 | |
| SCHEMBL16538462 | 0.79 | KMT2A (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | US | disclosed |
| EP-2437746-A2 | 17 BETA-ALKYL-17 ALPHA-OXY-ESTRATRIENES | Bayer Pharma Aktiengesellschaft (DE) | 2012-04-11 | — | — | EP | disclosed |
| WO-2010139411-A2 | 17β-ALKYL-17α-OXY-ESTRATRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010139411-A2 | 17β-ALKYL-17α-OXY-ESTRATRIENES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-09 | — | — | WO | disclosed |
| EP-2258375-A1 | 17B-alkyl-17alpha-oxy-estratrienes | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-12-08 | — | — | EP | disclosed |
| EP-2258375-A1 | 17B-alkyl-17alpha-oxy-estratrienes | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157421-A1 | 17Beta-Alkyl-17Alpha-oxy-estratrienes | CYP19A1, HSD17B11, CYP17A1 | HRH3 3889/4885CXCR4 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.